Showing results (21-30 of 78) with videos related to
Sort By:
Pageof 8
Oncotarget|February 12, 2015
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-αEyad Elkord, Deborah J Burt, Anette Sundstedt, et al.Current Gene Therapy|March 13, 2010
Building better chimeric antigen receptors for adoptive T cell therapyJohn S Bridgeman, Robert E Hawkins, Andreas A Hombach, et al.Human Gene Therapy Methods|August 13, 2013
Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancerErik M Alcantar-Orozco, Hannah Gornall, Vania Baldan, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancerAlaaeldin Shablak, Kanwal Sikand, Jonathan H Shanks, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2004
Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphomaAnne C Armstrong, Said Dermime, Kate Mulryan, et al.British Journal of Haematology|April 22, 2005
Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cellsEleanor J Cheadle, David E Gilham, Fiona C Thistlethwaite, et al.Immunological Reviews|December 17, 2013
CAR T cells: driving the road from the laboratory to the clinicEleanor J Cheadle, Hannah Gornall, Vania Baldan, et al.World Journal of Gastroenterology|April 19, 2014
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimensStephen J Hayes, Keng Ngee Hng, Peter Clark, et al.Clinical Immunology (Orlando, Fla.)|November 9, 2010
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cellsSameena Khan, Deborah J Burt, Christy Ralph, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complexJohn S Bridgeman, Robert E Hawkins, Steve Bagley, et al.Pageof 8